Chemistry Reference
In-Depth Information
74. Bendele A, Seely J, Richey C, Sennello G, Shopp G (1998) Renal tubular vacuolation in
animals treated with polyethylene-glycolconjugated proteins. Toxicol Sci 42:152-157
75. Veronese FM, Harris JM (2002) Introduction and overview of peptide and protein pegylation.
Adv Drug Deliv Rev 54:453-456
76. Duncan R (2006) Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer
6:688-701
77. Duncan R, Gilbert HRP, Carbajo RJ, Vicent MJ (2008) Polymer masked-unmasked protein
therapy (PUMPT) 1. Bioresponsive dextrin-trypsin and -MSH conjugates designed for
α
-
amylase activation. Biomacromolecules 9:1146-1154
78. Sakurai K, Miyazaki K, Kodera Y, Nishimura H, Shingu M, Inada Y (1997) Anti-inflammatory
activity of
superoxide dismutase conjugated with sodium hyaluronate. Glycoconj
J
14:723-728
79. Pyatak PS, Abuchowski A, Davis SS (1980) Preparation of a polyethylene glycol: superoxide
dismutase adduct, and an examination of its blood circulating life and anti-inflammatory
activity. Res Commun Chem Pathol Pharmacol 29:113-127
80. White CW, Jackson JH, Abuchowski A, Kazo GM, Mimmack RF, Berger EM, Freeman BA,
McCord JM, Repine JE (1989) Polyethylene glycol-attached antioxidant enzymes decrease
pulmonary oxygen toxicity in rats. J Appl Physiol 66:584-590
81. Walther FJ, Nunez FL, David-Cu R, Hill KE (1993) Mitigation of pulmonary oxygen toxicity
in instillation of polyethylene glycol-conjugated antioxidant en-zymes. Pediatr Res
33:332-335
82. Lapcik JL, Lapcik L, De Smedt S, Demeesters J, Chabrecek P (1998) Hyaluronan: preparation,
structure, properties, and applications. Chem Rev 98:2663-2684
83. Kaur I, Smitha R (2002) Penetration enhancers and ocular bioadhesives: two new avenues for
ophthalmic drug delivery. Drug Dev Ind Pharm 28:353-369
84. Saettone M, Chetoni P, Torracca M, Burgalassi S, Giannaccini B (1989) Evaluation of muco-
adhesive properties and in vivo activity of ophthalmic vehicles based on hyaluronic acid. Int J
Pharm 51:203-212
85. Liao YH, Jones SA, Forbes B, Martin GP, Brown MB (2005) Hyaluronan: pharmaceutical
characterization and drug delivery. Drug Deliv 12:327-342
86. Zhou B, Weigel JA, Fauss LA, Weigel PH (2000) Identification of the hyaluronan receptor for
endocytosis (HARE). J Biol Chem 275:37733-37741
87. Banerji S, Ni J, Wang SX, Clasper S, Su J, Tammi R, Jones M, Jackson DG (1999) LYVE-1 a
new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J Cell
Biol 144:789-801
88. Kim KS, Hur W, Park SJ, Hong SW, Choi JE, Goh EJ, Yoon SK, Hahn SK (2010) Bioimaging
for targeted delivery of hyaluronic acid derivatives to the livers in cirrhotic mice using
quantum dots. ACS Nano 4:3005-30014
89. Yang JA, Park K, Jung H, Kim H, Hong SW, Yoon SK, Hahn SK (2011) Target specific
hyaluronic acideinterferon alpha conjugate for the treatment of hepatitis C virus infection.
Biomaterials 32:8722-8729
90. Bailon P, Palleroni A, Schaffer CA, Spence CL, Fung WJ, Porter JE, Ehrlich GK, Pan W, Xu
ZX, Modi MW, Farid A, Berthold W (2001) Rational design of a potent, long-lasting form of
interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the
treatment of hepatitis C. Bioconj Chem 12:195-202
91. Foser S, Schacher A, Weyer KA, Brugger D, Dietel E, Marti S, Schreitm¨ ller T (2003)
Isolation,
structural characterization, and antiviral activity of positional
isomers of
monopegylated interferon alpha-2a (PEGASYS). Protein Expr Purif 30:78-87
92. D'Este M, Renier D, Pasut G, Rosato A (2010) Process for the synthesis of conjugates of
glycosaminoglycanes (GAG) with biologically active molecules polymeric conjugates and
relative uses thereof. IWO Patent Application 145821A1
